This ADC is composed of a trastuzumab-derived antibody and a potent auristatin derivative [134,135], which has been shown to have antitumor activity in HER2+ and HER2-low breast, lung, and gastric cancer [135,136]. Here, ERBB2 is linked to gastric cancer.